- Home
- RIME vs ONCT Comparison
RIME vs ONCT Comparison
Compare RIME & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- ONCT
- Stock Information
- Founded
- RIME 1982
- ONCT N/A
- Country
- RIME United States
- ONCT United States
- Employees
- RIME N/A
- ONCT N/A
- Industry
- RIME
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- RIME
- ONCT Health Care
- Exchange
- RIME NYSE
- ONCT Nasdaq
- Market Cap
- RIME 4.9M
- ONCT 4.3M
- IPO Year
- RIME 1994
- ONCT N/A
- Fundamental
- Price
- RIME $0.23
- ONCT $1.13
- Analyst Decision
- RIME
- ONCT Buy
- Analyst Count
- RIME 0
- ONCT 3
- Target Price
- RIME N/A
- ONCT $10.00
- AVG Volume (30 Days)
- RIME 790.7K
- ONCT 157.5K
- Earning Date
- RIME 11-26-2024
- ONCT 11-06-2024
- Dividend Yield
- RIME N/A
- ONCT N/A
- EPS Growth
- RIME N/A
- ONCT N/A
- EPS
- RIME N/A
- ONCT N/A
- Revenue
- RIME $37,788,657.00
- ONCT $2,161,000.00
- Revenue This Year
- RIME N/A
- ONCT $113.76
- Revenue Next Year
- RIME N/A
- ONCT N/A
- P/E Ratio
- RIME N/A
- ONCT N/A
- Revenue Growth
- RIME 24.99
- ONCT 227.92
- 52 Week Low
- RIME $0.22
- ONCT $1.03
- 52 Week High
- RIME $1.97
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- ONCT 37.09
- Support Level
- RIME N/A
- ONCT $1.03
- Resistance Level
- RIME N/A
- ONCT $1.30
- Average True Range (ATR)
- RIME 0.00
- ONCT 0.19
- MACD
- RIME 0.00
- ONCT -0.01
- Stochastic Oscillator
- RIME 0.00
- ONCT 13.70
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.